About US
Contact us
-
Sanofi Pasteur's dengue vaccine Dengvaxia gets approval in PhilippinesSanofi Pasteur has received marketing approval from the Philippines' Food and Drug Administration for Dengvaxia to prevent all four dengue types in individuals aged from nine to 45 years and living in2016/1/4
-
Bayer and CRISPR to form JV to develop new treatments for serious genetic diseasesBayer has entered an agreement with CRISPR Therapeutics to establish a joint venture (JV) to develop new breakthrough therapeutics for curing blood disorders, blindness and congenital heart disease.2016/1/4
-
CFDA issues Naming Rules for Medical Device Generic NameChina Food and Drug Administration (CFDA) recently issued the Naming Rules for Medical Device Generic Name, which will be implemented as of April 1, 2016.2015/12/31
-
Evonik strengthens its German sitesMore than EUR 400 million invested in 2015 Further large-scale projects in the local market planned for 2016 Engel, Chairman of the Executive Board: "By investing in growth and modernization in Ge2015/12/30
-
Boehringer Ingelheim will hire 400, invest €500M in Vienna biologics operationGermany'sBoehringer Ingelheimhas been swapping out operations and changing up top management as it scrambles to recover from patent losses that have flattened its revenues. After doing deals to bolste2015/12/29
-
GSK's new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog saysGlaxoSmithKline ($GSK) has a new drug that's tailored for patients with a specific type of severeasthma. But according to a nonprofit body that evaluates drugs' prices against their clinical effective2015/12/29
-
GSK adds Bristol-Myers pipeline drugs to challenge Gilead in HIVIt wasn't all that long ago that GlaxoSmithKline ($GSK) was considering a spinoff for its HIV drugs division,ViiV Healthcare. Now, though, the company is hanging on tight to that business--and buildin2015/12/28
-
Merck's Keytruda lines up its survival data for stepped-up battle with BMS' OpdivoThe rivalry is heating up between Merck & Co.'s ($MRK) immuno-oncology drugKeytrudaand its counterpart from Bristol-Myers Squibb ($BMY),Opdivo, in lung cancer. Long expected to dominate, Opdivo ha2015/12/28
-
Brace yourselves: The drug pricing brouhaha isn't dying downWho's tired of talking about drug prices? Many pharma types would raise their hands at that question. It was already a sore subject, what with Gilead Sciences' ($GILD) infamous $1,000-per-pill hepatit2015/12/25
-
Think we've seen the last of pharma's M&A tidal wave? Think againIf you think 2015 was a big year in pharma M&A, just wait. That train won't be slowing down any time soon, industry watchers say. On the contrary, they're expecting even more deal activity next ye2015/12/25